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A b s t r a c t
Background: Well designed cardiovascular disease (CVD) prevention programmes appear to be generally applicable and 
effective in reducing exposure to risk factors and the incidence of disease. However, introducing them broadly into clinical 
practice would have a significant impact on the healthcare budget, and requires careful consideration.
Aim: The purpose of this health economic analysis was to assess the potential cost-effectiveness of the model nurse-led, 
comprehensive CVD primary prevention programme which was prepared and introduced in the EUROACTION project, in 
high-risk patients in Poland. 
Methods: A Markov model was developed to assess the long-term costs of preventive intervention. The health states modelled 
were: event-free (all patients at the beginning of observation), stable angina first year, acute myocardial infarction, stable angina 
subsequent year, myocardial infarction subsequent year, CVD death, and other causes of death. Health benefits from the 
reduction in risk factors were estimated based on Framingham risk function assuming the probability of defined health states 
according to British registers. The time horizon of the analysis was ten years, and one Markov cycle length was one year. The 
analysis was prepared from the healthcare payer’s perspective. A willingness to pay threshold of three gross domestic product 
(GDP) per capita / quality-adjusted life years (QALY) was used. Univariate sensitivity analysis was conducted. Results were 
presented as an incremental cost-effectiveness ratio (ICER) expressed as an incremental cost per QALY.
Results: In Poland, EUROACTION intervention resulted mainly in reductions in the prevalence of smoking (by 14%) and high 
blood pressure (by 7%). Intervention on other risk factors, including blood lipids, was found to be less effective. Estimated 
ICERs were 19,524 PLN for men and 82,262 PLN for women. The programme was even more cost-effective in smokers i.e. 
estimated ICERs were 12,377 PLN in men and 53,471 PLN in women. The results were most sensitive to variations in health 
states utilities and cost value range as well as the duration of treatment effect. 
Conclusions: The model nurse-led, comprehensive CVD primary prevention programme developed in the EUROACTION 
project appears to be potentially highly cost-effective for high-risk male patients in Poland (below 1 GDP per capita per QALY). 
For women, the cost-effectiveness was less but still below the acceptable threshold (below three GDP per capita per QALY), 
although the sensitivity analysis showed that results were a subject of some uncertainty. 
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INTRODUCTION
Mortality due to coronary heart disease (CHD) has been de-
creasing in Poland since 1991 [1]. However, the prevalence of 
CHD is still high, due to prolonged life expectancy and longer 
survival after CHD events. From the economic perspective, 
CHD imposes a great cost for the National Health Fund (NHF) 
and Polish society. In 2005, the total cost of CHD in Poland 
was estimated to be €2,056.7 million [2]. Evidently, there is 
a clinical and economic imperative to develop effective strate-
gies in order to reduce the total burden of CHD. 
The recent study of primary prevention in Poland showed 
that the effectiveness of the routine management of risk 
factors in usual care is low [3]. The National Programme of 
Cardiovascular Disease Prevention, introduced by NHF, ap-
peared to be effective in identifying high-risk patients, but 
far less effective in risk factor control. The final conclusion 
of this study, which was carried out within the framework of 
the POLKARD project of the Polish Ministry of Health, was 
that there is an urgent need to introduce an effective and 
structured intervention on risk factors [3].
Preventive intervention is widely recognised as an effec-
tive way to reduce the incidence and progression of CHD. 
Nonetheless, there have been only a few attempts at con-
trolled intervention on risk factors in Poland. Recently, Poland 
has taken part in the EUROACTION project, an international 
initiative demonstrating that control of risk factors, lifestyle 
changes and therapeutic goals defined in the guidelines for 
cardiovascular prevention are achievable in everyday clini-
cal practice [4, 5]. The methods of intervention applied in 
the EUROACTION project could serve as a model solution. 
However, the cost-effectiveness of such an intervention is 
not known. And to date there has been no analysis on the 
cost-effectiveness of prevention programmes in Poland. 
The purpose of this study was therefore to assess the 
potential cost-effectiveness of a nurse-led, comprehensive 
cardiovascular disease (CVD) primary prevention programme 
which was prepared and introduced as part of the EURO-
ACTION project involving high-risk patients in Poland. 
METHODS
This analysis concerned the Polish component of the primary 
care of the EUROACTION project which was conducted 
between 2003 and 2006 in eight European countries. 
The main objective of the project was to help people at 
high risk of CHD to achieve the recommended lifestyle, to 
increase compliance with cardioprotective medication, to 
improve the control of risk factors, and to help reach thera-
peutic goals for CHD prevention. The project was a cluster 
randomised clinical trial and the intervention programme 
consisted of a one-year comprehensive preventive intervention 
co-ordinated by specially trained nurses. Patients from both 
groups (intervention and usual care) were invited for reassess-
ment after one year [4, 5]. Health benefits of the intervention 
for this analysis were assessed using the percentage of changes 
in risk factor levels observed in patients taking part in the Polish 
EUROACTION study in combination with the Framingham risk 
function to predict the reduction in cardiovascular events [6]. 
In order to assess the long term costs and health benefits of 
the EUROACTION-model intervention, a Markov model was 
developed assuming that changes in risk profiles of patients as 
surrogate outcomes recorded in the trial would result in a cor-
responding change in clinical outcomes and that the immediate 
effects of the intervention would persist over the following ten 
years (Fig. 1). The analysis was done from the health insurer’s 
perspective. The cycle length was one year. The main outcome 
measure modelled was quality-adjusted life years (QALY) 
gained. Results were presented in terms of the incremental 
cost-effectiveness ratio (ICER) which determines the additional 
cost of introducing intervention per QALY gained compared 
to usual care. The ICER was calculated as the difference in 
costs divided by the difference in effectiveness expressed in 
QALY. The cost-effectiveness threshold was set at the level of 
3 × gross domestic product (GDP) per capita according to the 
previously accepted recommendation of the World Health Or-
ganisation Commission on Macroeconomics and Health (www.
who.int/choice/costs/CER_thresholds/en/index.html [cited 
2010 Mar 30]), which gave the value of the threshold in Poland 
at time of analysis as 99,543 PLN per QALY gained (for GDP 
33.181 PLN, www.stat.gov.pl/cps/rde/xbcr/gus/PUBL_f_po-
land_in_figures_2009.pdf [cited 2010 Mar 3]). Following the 
recommendation of the Polish Agency for Health Technology 
Assessment (AHTA-Pol), discount rates of 5% and 3.5% were 
applied to costs and health benefits respectively (AHTA-Pol, 
2009; www.aotm.gov.pl [cited 2010 Apr 2]).  Half cycle cor-
rection was applied. Univariate sensitivity analysis was con-
ducted. Wherever possible, Polish-specific data was used; if 
not available, the best evidence from other settings was used. 
The model included two hypothetical cohorts of 
1,000 people at high risk of CHD for ten years after they were 
Figure 1. Structure of Markov model; SA — stable angina;  
SA sub. year — stable angina subsequent year; CHD — coro-
nary heart disease; AMI — acute myocardial infarction; AMI 
sub. year — acute myocardial infarction subsequent year
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involved in one-year intervention or monitored in usual care. It 
was assumed that, during the intervention, changes in risk factor 
levels were the same as observed in the EUROACTION study. 
The immediate effects of the intervention resulted in lower 
absolute risk of a primary CHD event in the intervention cohort 
at the beginning of the Markov model. CHD was defined as the 
onset of stable angina (SA), a non-fatal myocardial infarction 
(MI) and death from CHD-related causes. The health states 
modelled were: event-free, SA first year, acute myocardial 
infarction (AMI), SA subsequent year, MI subsequent year, 
CHD death, and other causes of death. It was assumed that all 
patients entered the Markov model in an event-free health state 
and that every third AMI was fatal (Fig. 1). To determine distribu-
tion to specific CHD events, in the absence of published Polish 
data, age- and gender-dependent incidence rates of primary 
events and transition probabilities of secondary events were de-
rived from British registries [7]. The probability of transition from 
SA to AMI and CHD death was calculated using constant rate 
(SA to AMI = 0.011, and SA to CHD death = 0.007 at the age 
of 67 years), in combination with changes in incidence rates to 
calculate probabilities by age. The transition probabilities from 
non-fatal AMI, and MI subsequent year to secondary AMI or 
CHD death were taken directly from Ward et al. [7]. The prob-
ability of dying from non-CHD causes was derived from Life 
Tables (http://www.stat.gov.pl/gus/5840_894_ENG_HTML.htm 
[cited 2009 Dec 20]), adjusted for the age-specific mortality 
due to CHD, reported in the official national mortality statistics 
[8]. All costs were estimated according to the real costs of the 
EUROACTION project from 2010 and expressed in Polish zloty 
(PLN). The cost of the intervention programme was calculated 
excluding the costs related to the research part of the EURO-
ACTION project. Average cost per patient was calculated by 
totalling all costs in the intervention year and dividing by the 
number of patients. Total costs included: pre-intervention cost, 
programme delivery cost, cost of final assessment, and cost of 
pharmacological treatment. The pre-intervention cost included: 
cost of training for nurses, time needed for eligibility assessment 
from medical records, costs of invitation, and cost of baseline 
assessment (nurse’s time — on average 45 min per patient, 
‘Smokerlyzer’, questionnaires and laboratory tests). Baseline 
screening included: assessment of lifestyle, medical history, use 
of medications, measurements of blood pressure, waist circum-
ference, height and weight, and blood collection for the deter-
mination of blood lipids and glucose concentration. Programme 
delivery costs included: the time of the health professionals, 
phone calls, printed materials, and laboratory tests. Cost of final 
assessment included: invitation phone calls, the nurse’s time 
(on average 30 min per patient), questionnaires and laboratory 
tests. Average salaries of health professionals were taken from 
publications of the Central Statistical Office of Poland (http://
www.stat.gov.pl/english/gus/praca_ludnosc [cited 2010 Feb 6]) 
and inflated to the present day using the  Consumer Price Index 
(http://www.stat.gov.pl/gus/5840_7507_ENG_HTML.htm [cited 
2010 Feb 6]). For the costs of laboratory assays, laboratories 
from different regions of Poland were contacted and finally the 
average prices from four laboratories serving a large numbers 
of patients were accepted. The price of telephone calls was 
taken from the website of the main Polish telephone provider 
(TP SA). The prices of printed materials were provided from a lo-
cal printing company based on a sample of the EURO ACTION 
materials. The price of the Smokerlyzer was obtained from the 
official Bedfont distributor for Poland. The cost of training was 
calculated based on current practices and prices of training for 
health professionals in Krakow (Table 1). The cost of pharma-
cotherapy was calculated from patients’ individual data, taking 
into account medication type and recommended daily dose. It 
was assumed that lifestyle changes were initiated in all patientsat 
the beginning of the intervention. If those changes were not 
sufficient within the first two months, patients were prescribed 
more intensive therapy. The total annual cost of intervention was 
estimated at 329.00 PLN per patient (Table 2). The cost of usual 
Table 1. Cost of the intervention programme without medications
Cost category   Price per 
unit (PLN)
Total 
(PLN)
Training for nurses 2,360.00
Equipment 2,000.00
Nurse’s time [h] 924.2 17.20 15,896.24
GP’s time [h] 148 27.00 3,996.00
Phone calls [min] 7,660 0.19 1,455.40
Questionnaires 466 1.00 466.00
Blood glucose tests 634 8.00 5,072.00
Blood lipids tests 930 24.00 22,320.00
Printed materials [set] 233 8.10 1,887.30
Total   55,452.94
Cost per patient   238.00
GP — general practitioner
Table 2. Summary of costs
Cost category PLN (2010)
Intervention group (medication included) 329.00
Usual care group (intervention year) 116.70
Stable angina, first year 1,295.00
Stable angina, subsequent year 697.00
Acute myocardial infarction 8,613.00
Myocardial infarction, subsequent year 697.00
Coronary heart disease death 2,911.00
Other causes of death 0.00
Event free state, usual care, post-intervention years 116.70
Event free state, intervention group,  
post-intervention years
135.00
www.kardiologiapolska.pl
Cost-effectiveness of a CVD primary prevention
705
care during the intervention year was calculated assuming that 
high-risk people under usual care have at least one doctor’s 
consultation and one set of blood tests per year. It was also as-
sumed that patients in the usual care cohort did not have any 
change in therapy during the intervention year.
The cost of the usual care was calculated at 116.70 PLN 
per patient (Table 2). The cost of event-free health state in the 
following years was calculated assuming that patients in both 
cohorts had the same frequency of attending general practice 
after the intervention year (a minimum of one doctor’s con-
sultation and one blood test per year), but that the difference 
in pharmacotherapy costs persists over time, regardless of 
any future changes. The cost of event-free health state was 
calculated as 116.70 PLN in usual care and 135.00 PLN in 
the intervention cohort. The annual cost of SA was derived 
from the study on costs related to diagnostics and treatment 
of coronary artery disease in Poland on an outpatient basis 
[2]. The average cost was calculated by totalling the reported 
annual costs of a doctor’s consultations, laboratory tests and 
medications. The cost of diagnostic treatment was included 
in the cost of SA in the first year only, assuming that regular 
monitoring would be sufficient in subsequent years. This cal-
culation gave the amount of 1,295.00 PLN (per patient per 
annum) for the first year SA and 697.00 PLN for SA subsequent 
year. In this analysis, an attempt was made to estimate the 
average cost of AMI from data on current system of payment 
for services to healthcare providers in Poland and data from 
the Polish Registry of Acute Coronary Syndromes (PL-ACS) [9]. 
All cases of AMI were classified in several diagnosis related 
groups (DRG) (Table 3), to which the costs of in-hospital phar-
macotherapy were already assigned. The cost after discharge 
was assumed to be the same for SA subsequent year. Applying 
a point value for 2010 (51.00 PLN), and the proportions of 
patients having ST elevation myocardial infarction (STEMI; 
0.54) and non-STEMI (0.46) [9], the average annual cost of 
AMI per patient was calculated as 8,613.00 PLN. The cost 
of MI subsequent year was assumed to be the same for SA 
subsequent year, 697.00 PLN. The cost of CHD death was 
calculated based on estimates that 50% of CHD deaths are 
sudden cardiac deaths [10] and that 40% of those deaths occur 
without witnesses and therefore without chances for resus-
citation [11]. For the purpose of the analysis, it was assumed 
that 20% of CHD deaths happened without any contact with 
healthcare professionals;  to account for the proportion of 
patients who die before emergency care reaches them, it was 
assumed that the remaining 80% of deaths generated the cost 
of fatal MI without revascularisation. The cost of CHD death 
was calculated as 2,911.00 PLN. A summary of all costs is 
presented in Table 2. As health-related quality of life (HRQoL) 
in the general population normally decreases with age, a linear 
correlation [7] derived from data on the UK general popula-
tion [12] was used to adjust utility of event-free state by age: 
utility by age =1.06 – 0.004 × age. Utility weights for the 
first year health states were taken from relevant studies [13, 
14]. To account for an increase in HRQoL among patients 
with CHD over time, especially among those who underwent 
revascularisation and cardiac rehabilitation, higher utility 
weights were assigned to the health states in subsequent years 
suggested in previously published cost-effectiveness studies 
[15–18]. For the secondary event, it was assumed that a pa-
tient had an additional reduction in utility weight of 10% [15]. 
The first Polish general utility values derived from the EQ-5D 
questionnaire were published in 2010 [19, 20], expressed 
as a mean value for each age group in ten yearintervals [19]. 
Although the authors stated several weaknesses of their study 
(small sample size and questionable representativeness of the 
sample), those values were included in sensitivity analysis as 
utility values of the event-free health state by age. A summary 
of all utility weights used in analysis is presented in Table 4.
Base case analysis considered the cost-effectiveness 
of the intervention offered to men and women who were 
57 years old, with the average baseline risk profile of Polish 
Table 3. In-hospital treatment of patients with acute myocardial infarction
Type of treatment DRG 
group
Proportion 
of NSTEMI 
patients
Proportion 
of STEMI 
patients
Points 
NSTEMI
Points 
STEMI
Thrombolysis performed as the only reperfusion therapy  E19 0.006 0.078 135 135
Glycoprotein IIb/IIIb inhibitor 0.031 0.159 63 63
Coronary angiography performed but without subsequent PCI E27 0.086 0.037 32 32
PCI as a complex treatment (angiography, thrombolysis, stents) E12 0.231 0.555 265 265
CABG E06 0.056 0.045 384 384
Treatment without revascularisation  
NSTEMI E18 0.621 30  
STEMI E17   0.285   37
DRG — diagnosis related groups; STEMI — ST elevation myocardial infarction; NSTEMI — non-ST elevation myocardial infarction; PCI — percuta-
neous coronary intervention; CABG — coronary artery bypass grafting
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patients involved in the EUROACTION study (systolic blood 
pressure = 141.09 mm Hg, total cholesterol = 6.05 mmol/L, 
HDL = 1.56 mmol/L) and without additional risk factors, who 
achieved mean percentage reduction in risk factor levels. As 
many EUROACTION patients were smokers at baseline, 
one analysis was done adding smoking as a risk factor to the 
average risk profile.
RESULTS
In the Polish component of the EUROACTION project, in the 
intervention general practice, 278 eligible patients were identi-
fied,  of whom 256 attended baseline screening and 233 had 
a full final assessment. In usual care practice, 320 eligible pa-
tients were identified and a random sub-sample of 80 patients 
were invited for a baseline screening, of whom 44 participated 
in baseline screening; 28 of those 44 participated in a one year 
follow-up. An additional 133 patients in usual care practice 
underwent only the final assessment. Data on 233 patients 
from the intervention clinic and 28 patients from the usual 
care for whom complete information was available at the 
end of the one-year follow-up period was used in the present 
study. Descriptive statistics for risk factors and treatments in the 
intervention and usual care groups are given in Table 5. In the 
intervention group, pharmacotherapy was initiated in 8.15% 
of previously untreated patients. There was an increase in 
the prescription of angiotensin-converting enzyme inhibitors, 
statins and diuretics. In the usual care group, there were no 
significant changes in therapy. The proportion of patients who 
reached the treatment target for blood pressure increased to 
72.5% in the intervention group and to 50% in the usual care 
group (relative change was 28%, 95% CI 14.7–41.2). The pro-
portion of patients who achieved the treatment target for total 
cholesterol in the intervention group increased to 22.7%, but 
the increase in the usual care group was similar and the rela-
tive change was not significant (0.004, 95% CI –13.7 to 14.5). 
EUROACTION intervention resulted mainly in a reduction of 
the prevalence of smoking (by 14%) and of high blood pres-
sure (by 7% on average). In contrast to men, women achieved 
a decrease in total cholesterol concentration, but a greater 
decrease in HDL-cholesterol was observed as well. Reduction 
in cardiovascular risk factors (as a percentage of change from 
baseline) is presented by sex in Table 6. The model estimated 
that over the period of ten years, a cohort of people who 
would undergo the intervention programme would gain greater 
health benefits compared to a cohort of people under usual 
care, but that this would increase the cost for NHF. After ap-
plying discount rates, an estimated ICER was 19,524 PLN for 
men and 82,262 PLN for women (Table 7). For smokers, the 
cost-effectiveness was even higher as discounted ICERs were 
12,377 PLN for men and 53,471 PLN for women (Table 7). 
The results of the univariate sensitivity analyses are presented in 
Table 8. The model displayed the highest sensitivity to changes 
of health states utilities and duration of intervention effects. In 
women, if the effect of the intervention lasts shorter than the 
assumed ten years, the intervention would probably exceed 
the cost effectiveness threshold. For example, for five years the 
cost for QALY would be twice as high as the threshold value 
of three GDPs.
DISCUSSION
Our analysis shows that despite a relatively small effect on 
risk factors, offering the EUROACTION model intervention to 
patients at high risk of CHD in Poland would yield potentially 
an extra quality-adjusted year of survival at a cost of QALY for 
less than one GDP per capita (33,181 PLN) for men. Results 
Table 4. Utilities used in analysis
Health state Utility weight Source
Stable angina, first year 0.8 [14]
Acute myocardial infarction 0.7 [13, 15]
Stable angina, subsequent year 0.9 [15, 17, 18]
Myocardial infarction,  
subsequent year
0.8 [15, 16]
Utility of event-free state by age = 1.06–0.004  
¥ age
[7, 12]
Polish-specific utility values for event-free  
state by age used in sensitivity analysis 
Age group 45–54 0.9
Age group 55–64 0.894 [19, 20]
Age group ≥ 65 0.798
Table 5. Baseline assessment of patients enrolled in Polish 
primary care of the EUROACTION project
Intervention Usual care
Age [years] 56.5 ± 5.8 57.0 ± 6.9
Male 96 (41%) 16 (57%)
SBP [mm Hg] 141.1 ± 17.2 139.9 ± 12.7
TC [mmol/L] 6.05 ± 0.97 5.42 ± 0.69
HDL-C [mmol/L] 1.56 ± 0.39 1.49 ±0.37 )
Current smokers 103 (44.2%) 9 (32.1%)
Diabetics 27 (11.6%) 3 (10.7%)
BP < 140/90 mm Hg, and  
< 130/85 mm Hg in diabetics
87 (37.3%) 12 (42.9%)
TC  < 5 mmol/L 27 (11.6%) 8 (28.6%)
Cardioprotective drugs 132 (56.7%) 19 (67.9%)
Beta-blockers 55 (23.6%) 4 (14.3%)
ACEI 89 (38%) 10 (35.7%)
Statins 48 (20.6%) 5 (17.9%)
SBP — systolic blood pressure; TC — total cholesterol, HDL-C —  high 
density lipoprotein cholesterol; ACEI — angiotensin converting enzyme 
inhibitors; BP — blood pressure
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for women were significantly higher, but the majority of them 
were still below the acceptable threshold of three GDP per 
capita, and they should be interpreted with more caution as 
results derived under the assumption that utility weights of the 
health states are 10% higher than in the base case analysis and 
that the intervention effect lasts for five years, exceeding the 
suggested threshold. Costs of a QALY were lower in smokers 
and in older people, thus confirming that cost-effectiveness 
increased with higher baseline absolute risk. 
The estimated ICERs differed significantly between men 
and women at the same age, which was to be expected 
considering that the absolute risk of CHD and consequently 
the amount of QALYs gained by introducing the intervention, 
was much higher for men than for women. 
A relatively small number of published studies have ad-
dressed the cost-effectiveness of multifactorial interventions 
for prevention in usual care, and there have been many dif-
ferences among them in terms of intervention type, settings, 
sample populations, perspective and economic methods 
employed. The design and objective of EUROACTION dif-
fered significantly from all interventions evaluated previously 
and comparisons are not straightforward.
Sensitivity analysis showed that if the results of interven-
tion are the same as the EUROACTION average, cost-effec-
tiveness would be even higher compared to the total EURO-
ACTION study group, Polish patients were younger and the 
proportion of females was higher. At baseline assessment, they 
had higher mean total cholesterol level and the proportion of 
smokers was higher than in the overall EUROACTION study 
group. A lower proportion of patients in Poland was classi-
fied as diabetics. The one-year follow-up assessment showed 
that Polish patients achieved greater decreases in systolic 
blood pressure than the whole EUROACTION study group 
(–10 vs. –7.6 mm Hg), a similar decrease in total cholesterol al-
though from a higher baseline level, and 14 out of 103 (13.6%) 
smokers at baseline quitted smoking. Polish patients showed 
a definite decrease in blood HDL-cholesterol [4, 5].
Interpretating these results must be carried out with cau-
tion. The effectiveness of the intervention was estimated based 
on the difference in the reduction of risk factors between the 
intervention group and the usual care group. There is some 
uncertainty about the transferability of risk factors changes 
into reductions in CHD events. Future studies, with a larger 
sample size and longer follow-up in order to capture clini-
cal outcomes, are essential to validate the number of events 
predicted by this model. Furthermore, our control group was 
very small, and the presence of outliers could have changed 
the estimation of effectiveness significantly. The model was 
also based on the assumption that the effect of intervention 
persisted over ten years. Some previous studies have shown 
that the effects of less intensive interventions have been sus-
tained over at least three or six years [21, 22], however, the 
Table 6. Change in the main cardiovascular disease risk factors
Patients Number Percentage of change from baseline level
Systolic blood 
pressure 
Total  
cholesterol
HDL  
cholesterol
Quitted smoking  
(% of smokers)
Men
Intervention 96 –7.37 –4.53 –4.48 11
Usual care 16 0.22 –4.46 –4.22 0
Women
Intervention 137 –7.44 –6.32 –18.13 15.5
Usual care 12 –4.95 –1.46 –15.00 0
Table 7. Results of the base case analysis: incremental costs and QALYs for cohorts of 1,000 patients, 57 years old, profile  
SBP = 141.09; TC = 6.05 mmol/L; HDL-C = 1.57 mol/L non smokers, and smokers
Undiscounted Discounted
Incremental 
costs (PLN)
Incremental 
QALYs
ICER  
(PLN)
Incremental 
costs (PLN)
Incremental 
QALYs
ICER
(PLN)
Men (ns) 259,171.04 16.61 15,600.81 255,163.79 13.07 19,523.91
Women (ns) 347,492.35 4.95 70,236.64 319,289.12 3.88 82,261.84
Men (s) 213,829.02 22.77 9,390.02 221,990.86 17.94 12,377.28
Women (s) 327,155.19 7.26 45,071.11 304,602.39 5.70 53,470.97
SBP — systolic blood pressure; TC — total cholesterol; HDL-C — high density lipoprotein cholesterol; PLN — New Polish zloty (2010 values);  
ICER — incremental cost per quality-adjusted life years (QALY); ns — non smokers; s — smokers
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Table 8. Summary of the results of the univariate sensitivity analyses for cohorts of men and women, 57 years old, with the  
average risk profile: SBP = 141.09, TC = 6.05 mmol/L, HDL-C = 1.57 mmol/L discounted incremental cost per QALY, (PLN)
VALUE ICER (PLN)
Men Women
Base case
(discount rates 5% for costs, 3.5% for utilities) 19,523.91 82,261.84
Sensitivity analysis
Discount rates 0% for costs and utilities 15,600.81 70,236.64
5 % for costs and utilities 21,539.32 90,857.46
5% for costs. 0% for utilities 15,359.59 64,536.08
Costs
Cost of intervention (no change in medication) plus 20% 23,120.12 94,370.95
minus 20% 15,851.18 69,895.10
Cost of therapy in int. group plus 20% of initial increase 22,825.87 90,071.26
Increase in cost of therapy in usual care cohort
by 50% of increase in int. group during intervention year 14,134.61 62,991.55
by 50% of increase in int. group in the year after intervention 14,834.73 65,348.96
by 50% of increase in int. group five years after intervention 17,663.38 75,192.31
All health states costs plus 20% 18,208.91 80,886.70
minus 20% 20,839.19 83,637.15
Cost of AMI plus 20% 19,018.94 81,803.59
minus 20% 20,029.16 82,720.10
Cost of CHD death plus 20% 19,128.91 82,412.23
minus 20% 19,918.90 83,027.97
Cost of angina first year plus 20% 19,418.90 82,094.90
minus 20% 19,628.91 82,428.79
Cost of subsequent years plus 20% 19,213.87 81,819.61
minus 20% 19,833.94 82,704.08
Cost of MI subsequent year plus 20 % 19,411.71 75,321.84
Utilities of health states plus 10% 24,936.50 119,105.45
minus 10% 16,041.93 62,827.15
Constant utility by age 15,704.95 66,144.66
Constant utilities by age and utility of health states plus 10% 20,056.55 95,748.04
Constant utility by age and utilities of health states minus 10% 12,904.99 50,523.74
Utility by age using Polish-specific utility values [19, 20] 18,502.18 78,082.36
Duration of the effect
Effect of the intervention lasts 15 years   8,880.86 40,978.86
Effect of the intervention lasts five years 66,596.69 25,3117.7
Effectiveness of the intervention
Effectiveness as in the whole EUROACTION project   16,251.78 45,636.14
Distribution through primary events
Proportion of AMI  increases by 50% 19,452.87 81,017.28
Proportion of CHD deaths increases by 50% 16,698.04 72,379.78
Starting age of participants ± 5 years
Age 52 22,982.79 95,161.01
62 14,919.37 61,128.78
SBP — systolic blood pressure; TC — total cholesterol; HDL-C — high density lipoprotein cholesterol; PLN — New Polish zloty (2010 values);  
ICER — incremental cost per quality-adjusted life years (QALY); AMI — acute myocardial infarction; MI — myocardial infarction; CHD — coronary 
heart disease; int. — intervention
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exact duration of the EUROACTION effect is uncertain and 
could be established only by a longer prospective study. As 
Poland belongs to the group of European countries with high 
CHD risk, in this analysis it was assumed that the Framingham 
risk equations would predict the absolute CHD risk in Polish 
people reasonably well. However, Poland-specific validation 
is necessary to decrease the uncertainty about the accuracy 
of these predictions. The ability of the Framingham equations 
to capture a real value of the intervention as they include 
some, but not all, risk factors addressed by the EUROACTION 
intervention is a separate problem. The distribution data to 
primary events, transition probabilities of secondary events 
and utility weights were taken from published literature, 
which introduced additional uncertainty into the model. 
Poland-specific data, particularly on utility weights of health 
states first and subsequent years after an event, would bring 
much more accuracy to the analysis; thus these results should 
be reassessed when this data becomes available. 
On the other hand, the analysis was limited to CHD. 
Considering that the intervention on blood pressure could 
also have an effect on the incidence of cerebrovascular 
disease and that the intervention on smoking would have 
an effect on the incidence of lung cancer, it is likely that the 
inclusion of stroke, transient ischaemic attack and cancer in 
the analysis would yield to a further decrease in ICERs and 
that the EUROACTION model intervention would then be 
even more cost-effective. Polish patients in the study were of 
working age (mean 57 years) and it is likely that the inclusion 
of indirect costs could have a significant impact on the results 
and increase cost-effectiveness further. 
In the present analysis, utility weights for the first year 
health states were taken from international studies, but Polish 
general utility values have also been published. For the latter, 
the authors stated several weaknesses of their study including 
small sample size and questionable representativeness of the 
sample [19, 20]. Following this, Polish-specific values were 
used in the sensitivity analysis only. Also, the analysis was 
done from the health payer’s perspective and did not include 
costs borne by patients and non-medical costs for society. 
Another limitation was related to the level of motivation of 
the participants. People willing to participate in trials are 
likely to be highly motivated, and extrapolating results to all 
people at high risk in Poland should be done with caution. The 
weakness of the study is the absence of registry data for Polish 
patients with CVD, which is why UK data was used. However, 
the study by Daly et al. [23] which compared treatment and 
clinical outcomes of patients with SA in Poland and the UK, 
based on data from the Euro Heart Survey on stable angina, 
revealed that for one year of the study follow-up there were no 
significant differences in clinical outcomes (non-fatal MI, acute 
coronary syndrome and fatal CHD event) between Polish and 
UK patients. A less important weakness of our analysis is that 
the laboratory prices used can only be considered as typical 
for Poland, but they do not fulfill the requirement for being 
regarded as fully representative as they were not randomly 
selected from the full list of laboratories in Poland.
It is obvious that the greater the risk is, the higher the 
cost-effectiveness of the preventive procedure. It would be 
interesting to know the threshold value for the risk parameters 
which defines cost-effectiveness. However, we are unable to 
address this in our paper, which focuses on the problem of 
whether small changes in risk factors which are the common 
effect of preventive interventions could be cost-effective at all. 
CONCLUSIONS
The model, nurse-led, comprehensive CVD primary preven-
tion programme developed in the EUROACTION project 
appears to be potentially highly cost-effective for high-risk 
male patients in Poland (below one GDP per capita per QALY). 
For women, the cost-effectiveness was lower, but still below 
the acceptable threshold (below three GDP per capita per 
QALY), although the sensitivity analysis showed that results 
were subject to some uncertainty.
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Efektywność kosztowa programu pierwotnej 
prewencji chorób sercowo-naczyniowych  
w warunkach podstawowej opieki zdrowotnej. 
Wyniki polskiej części projektu EUROACTION
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S t r e s z c z e n i e
Wstęp: Prawidłowo zaplanowany program pierwotnej prewencji choroby niedokrwiennej serca (CVD) może istotnie obniżyć 
zachorowalność, jednak jego powszechne wdrożenie będzie miało znaczny wpływ na budżet opieki zdrowotnej i w związku 
z tym wymaga wcześniejszych analiz ekonomicznych.
Cel: Celem pracy było określenie kosztowej efektywności prowadzonego przez przeszkolone pielęgniarki kompleksowego 
programu pierwotnej prewencji CVD, który został opracowany i wdrożony w Polsce w ramach projektu EUROACTION u osób 
z wysokim ryzykiem sercowo-naczyniowym.
Metody: Koszty zastosowania programu pierwotnej prewencji CVD oceniono z wykorzystaniem modelu Markowa. W mo-
delu przyjęto następujące stany zdrowia: wolny od choroby (wszystkie osoby na początku obserwacji), dławica piersiowa 
w pierwszym roku, ostry zawał serca, dławica piersiowa w następnym roku, zawał serca w następnym roku, zgon w wyniku 
CVD i zgon z pozostałych przyczyn. Korzyści zdrowotne związane z obniżeniem poziomu czynników ryzyka oceniono 
z zastosowaniem funkcji ryzyka wg Framingham Study, przyjmując częstość występowania zdefiniowanych stanów zdrowia 
wg rejestru w Wielkiej Brytanii. Horyzont czasowy analizy ustalono na 10 lat, a długość pojedynczego cyklu określono na 
1 rok. Analiza została przygotowana z perspektywy płatnika. Przyjęto próg kosztowej efektywności na poziomie 3-krotnego 
produktu krajowego brutto (PKB) per capita. Przeprowadzono jednoczynnikową analizę wrażliwości. Wyniki zaprezentowano 
w postaci inkrementalnych współczynników kosztowej efektywności (ICER) przedstawiających koszt związany z uzyskaniem 
dodatkowego roku życia w pełnej jakości życia (QALY). 
Wyniki: W polskiej części projektu EUROACTION stwierdzono, że największą korzyścią z programu pierwotnej prewencji 
było obniżenie o 14% częstości palenia tytoniu i obniżenie o 7% odsetka osób z wysokim ciśnieniem tętniczym w całej gru-
pie. Wpływ na inne czynniki, w tym także stężenie lipidów osocza, był niewielki. Współczynniki ICER wynosiły 19 524 PLN 
u mężczyzn i 82 262 PLN u kobiet. U osób palących współczynniki ICER dla obu płci były niższe i wynosiły 12 377 PLN 
u mężczyzn i 53 471 PLN u kobiet. Wyniki były wrażliwe głównie na zmiany użyteczności przyjętych stanów zdrowotnych 
i zmiany wysokości niektórych kategorii kosztów, a także czasu trwania farmakoterapii. 
Wnioski: U mężczyzn z wysokim ryzykiem prowadzony przez pielęgniarki kompleksowy program pierwotnej prewencji CVD 
(opracowany w ramach projektu EUROACTION) może być wysoce kosztowo efektywną procedurą. U kobiet osiągnięcie tych 
samych wyników jest bardziej kosztowne, ale również poniżej założonego progu opłacalności (3 PKB per capita). Modelowy 
kompleksowy program pierwotnej prewencji opracowany w projekcie EUROACTION jest potencjalnie wysoce efektywny 
kosztowo u mężczyzn z grupy wysokiego ryzyka w Polsce (< 1 PKB per capita na QALY). U kobiet efektywność kosztowa jest 
niższa, choć nadal poniżej akceptowalnego progu (3 PKB per capita na QALY), a także wyniki analizy są obarczone niepew-
nością, co wykazano w ramach analizy wrażliwości. 
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